Cardiac Biomarkers Market by Types (Troponin, Creatine kinase - MB, Natriuretic peptides - B-type Natriuretic Peptide & N-terminal pro B-type Natriuretic Peptide, Myoglobin, Ischemia Modified Albumin (IMA), Heart-type Fatty Acid Binding Protein, and LDH Isoenzymes), Applications (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Cardiomyopathy, Ischemia, Myocarditis, and Atrial Fibrillation), End-users (Laboratory Testing and Point of Care (POC) Testing), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global cardiac biomarkers market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of cardiovascular diseases and increasing number of the geriatric population globally.
Cardiac biomarkers are types of proteins, which are released into the bloodstream from heart muscle. The biomarkers are released when the heart muscle is damaged due to a blocked artery. Cardiac biomarkers, as endogenous agents such as carbohydrates, hormones, and proteins, are released into the blood when the heart is weakened or nervous. They are mainly used to diagnose heart attacks, acute coronary syndrome (ACS), and other disorders including a lack of blood supply to the heart.
Troponin is one of the most widely adopted biomarkers for detecting heart injury among cardiac biomarker tests and troponin levels rise quickly after heart injury and remain up for up to two weeks. The test is done using a blood sample drawn from a vein in the hand or arm with a needle. The test, which takes several hours to complete, helps in the diagnosis of a heart attack. Cardiac biomarkers are used to stratify risk for a variety of cardiovascular disorders (CVDs) such as myocardial infraction, congestive heart failure, and acute coronary syndrome (ACS). CK-MB, troponin I and T, myoglobin, BNPs, IMA, and other cardiac biomarkers are commonly used in an integrated diagnostic approach for CVDs.
Market Trends, Drivers, Restraints, and Opportunities
- High accuracy, economic price, quick outcomes are some of the features of cardiac point of care (POC) testing. These factors are projected to boost the market growth during the forecast period.
- Increasing number of patients with diseases such as hypertension, dyslipidemia obesity, and diabetes, which poise major risk factors for cardiovascular disorders, are projected to propel the market growth.
- Increasing number of COVID-19 cases has affected the market as there has been a sharp decreased in the number of patients with cardiovascular disorders to opt for diagnosis. This is expected to hamper the market growth.
- Availability of other diagnostic methods for cardiovascular diseases and possibility of side effects of using biomarkers are major factors that can hamper the market growth.
- Increased R&D funding from public as well as private organizations is projected to create lucrative opportunities for the market players.
Scope of the Report
The report on the global cardiac biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Cardiac Biomarkers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Types (Troponin, Creatine kinase - MB, Natriuretic Peptides - B-type Natriuretic Peptide & N-terminal pro B-type Natriuretic Peptide, Myoglobin, Ischemia Modified Albumin, Heart-type Fatty Acid Binding Protein, and LDH Isoenzymes), Applications (Acute Coronary Syndrome, Myocardial infarction, Congestive Heart Failure, Cardiomyopathy, Ischemia, Myocarditis, and Atrial Fibrillation), and End-users (Laboratory Testing and Point of Care Testing) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., and Randox Laboratories Ltd. |
Market Segment Insights
Troponin segment is expected to constitute a key share of the market
Based on types, the cardiac biomarkers market is segmented into troponin, creatine kinase - mb (CK-MB), natriuretic peptides - b-type natriuretic peptide (BNP) & n-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, ischemia modified albumin (IMA), heart-type fatty acid binding protein (H-FABP), LDH isoenzymes. The troponin segment is expected to constitute a key share of the market during the forecast period owing to their benefits in detecting AMI and their effectiveness in diagnosing cardiovascular diseases in a timely and reliable manner compared to other tests, which help in preventing adverse cardiac events. On the other hand, the natriuretic peptides segment is anticipated to expand at a rapid pace during the forecast period due to its efficiency in accurately diagnosing CHF.
Acute coronary syndrome segment is expected to hold a major market share
On the basis of applications, the market is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure, cardiomyopathy, ischemia, myocarditis, and atrial fibrillation. The acute coronary syndrome segment is expected to hold a major share of the market during the forecast period owing to a high rate of acute coronary syndrome. On the other hand, the myocardial infarction segment is anticipated to expand at a rapid pace during the forecast period owing to increasing geriatric population the prevalence of an obese & sedentary lifestyle among individuals, smoking & alcohol intake, and unhealthy eating patterns, all of which eventually contribute to obesity.
Point of care segment is expected to expand at a rapid pace
Based on end-users, the cardiac biomarkers market is bifurcated into laboratory testing and point of care (POC) testing. The POC testing segment is expected to account for a key share of the market during the forecast period owing to increasing demand for POC test kits. These kits are compact and convenient as they are easy to use, making them as common medical equipment in the home healthcare segment.
North America is anticipated to dominate the market
In terms of regions, the cardiac biomarkers market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to the high prevalence of coronary heart disease in the region as well as the wide popularity of point-of-care diagnostics, which have resulted in a substantial disease burden.
On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing population and rising prevalence of cardiovascular diseases in this region. The advent of the cardiac biomarkers vertical in the region is expected to be fueled by this rapid development.
Segments
Segments Covered in the ReportThe global cardiac biomarkers market has been segmented on the basis of
Types
- Troponin
- Creatine Kinase - MB (CK-MB)
- Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
- Myoglobin
- Ischemia Modified Albumin (IMA)
- Heart-Type Fatty Acid Binding Protein
- LDH Isoenzymes
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Cardiomyopathy
- Ischemia
- Myocarditis
- Atrial Fibrillation
- Laboratory Testing
- Point of Care Testing
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Alere, Inc.,
- Siemens Healthcare GmbH
- Roche Diagnostics
- Beckman Coulter, Inc.
- Thermo Fisher Scientific, Inc.
- Becton, Dickinson and Company
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Randox Laboratories Ltd.
Competitive Landscape
Key players competing in the cardiac biomarkers market are Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., and Randox Laboratories Ltd.
These companies are constantly focusing on generating growth by creating innovative product designs and new tests as well as improving the specificity of the tests. Alere, Inc., for example, made the Alere triage line, which combines three important biomarkers: CK-MB, myoglobin, and troponin I. This test is easy to use and popular since it is a hybrid tool and an effective point-of-care cardiac testing package.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cardiac Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cardiac Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cardiac Biomarkers Market - Supply Chain
4.5. Global Cardiac Biomarkers Market Forecast
4.5.1. Cardiac Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cardiac Biomarkers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Cardiac Biomarkers Market Absolute $ Opportunity
5. Global Cardiac Biomarkers Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Cardiac Biomarkers Market Size and Volume Forecast by Types
5.3.1. Troponin
5.3.2. Creatine Kinase - MB (CK-MB)
5.3.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
5.3.4. Myoglobin
5.3.5. Ischemia Modified Albumin (IMA)
5.3.6. Heart-Type Fatty Acid Binding Protein
5.3.7. LDH Isoenzymes
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Cardiac Biomarkers Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Cardiac Biomarkers Market Size and Volume Forecast by Applications
6.3.1. Acute Coronary Syndrome
6.3.2. Myocardial Infarction
6.3.3. Congestive Heart Failure
6.3.4. Cardiomyopathy
6.3.5. Ischemia
6.3.6. Myocarditis
6.3.7. Atrial Fibrillation
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Cardiac Biomarkers Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Cardiac Biomarkers Market Size and Volume Forecast by End Users
7.3.1. Laboratory Testing
7.3.2. Point of Care Testing
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Cardiac Biomarkers Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cardiac Biomarkers Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cardiac Biomarkers Demand Share Forecast, 2019-2026
9. North America Cardiac Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cardiac Biomarkers Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cardiac Biomarkers Market Size and Volume Forecast by Types
9.4.1. Troponin
9.4.2. Creatine Kinase - MB (CK-MB)
9.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
9.4.4. Myoglobin
9.4.5. Ischemia Modified Albumin (IMA)
9.4.6. Heart-Type Fatty Acid Binding Protein
9.4.7. LDH Isoenzymes
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Cardiac Biomarkers Market Size and Volume Forecast by Applications
9.7.1. Acute Coronary Syndrome
9.7.2. Myocardial Infarction
9.7.3. Congestive Heart Failure
9.7.4. Cardiomyopathy
9.7.5. Ischemia
9.7.6. Myocarditis
9.7.7. Atrial Fibrillation
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Cardiac Biomarkers Market Size and Volume Forecast by End Users
9.10.1. Laboratory Testing
9.10.2. Point of Care Testing
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Cardiac Biomarkers Demand Share Forecast, 2019-2026
10. Latin America Cardiac Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Types
10.4.1. Troponin
10.4.2. Creatine Kinase - MB (CK-MB)
10.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
10.4.4. Myoglobin
10.4.5. Ischemia Modified Albumin (IMA)
10.4.6. Heart-Type Fatty Acid Binding Protein
10.4.7. LDH Isoenzymes
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Applications
10.7.1. Acute Coronary Syndrome
10.7.2. Myocardial Infarction
10.7.3. Congestive Heart Failure
10.7.4. Cardiomyopathy
10.7.5. Ischemia
10.7.6. Myocarditis
10.7.7. Atrial Fibrillation
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Cardiac Biomarkers Market Size and Volume Forecast by End Users
10.10.1. Laboratory Testing
10.10.2. Point of Care Testing
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Cardiac Biomarkers Demand Share Forecast, 2019-2026
11. Europe Cardiac Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cardiac Biomarkers Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cardiac Biomarkers Market Size and Volume Forecast by Types
11.4.1. Troponin
11.4.2. Creatine Kinase - MB (CK-MB)
11.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
11.4.4. Myoglobin
11.4.5. Ischemia Modified Albumin (IMA)
11.4.6. Heart-Type Fatty Acid Binding Protein
11.4.7. LDH Isoenzymes
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Cardiac Biomarkers Market Size and Volume Forecast by Applications
11.7.1. Acute Coronary Syndrome
11.7.2. Myocardial Infarction
11.7.3. Congestive Heart Failure
11.7.4. Cardiomyopathy
11.7.5. Ischemia
11.7.6. Myocarditis
11.7.7. Atrial Fibrillation
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Cardiac Biomarkers Market Size and Volume Forecast by End Users
11.10.1. Laboratory Testing
11.10.2. Point of Care Testing
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Cardiac Biomarkers Demand Share Forecast, 2019-2026
12. Asia Pacific Cardiac Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Types
12.4.1. Troponin
12.4.2. Creatine Kinase - MB (CK-MB)
12.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
12.4.4. Myoglobin
12.4.5. Ischemia Modified Albumin (IMA)
12.4.6. Heart-Type Fatty Acid Binding Protein
12.4.7. LDH Isoenzymes
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Applications
12.7.1. Acute Coronary Syndrome
12.7.2. Myocardial Infarction
12.7.3. Congestive Heart Failure
12.7.4. Cardiomyopathy
12.7.5. Ischemia
12.7.6. Myocarditis
12.7.7. Atrial Fibrillation
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by End Users
12.10.1. Laboratory Testing
12.10.2. Point of Care Testing
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Cardiac Biomarkers Demand Share Forecast, 2019-2026
13. Middle East & Africa Cardiac Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Types
13.4.1. Troponin
13.4.2. Creatine Kinase - MB (CK-MB)
13.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
13.4.4. Myoglobin
13.4.5. Ischemia Modified Albumin (IMA)
13.4.6. Heart-Type Fatty Acid Binding Protein
13.4.7. LDH Isoenzymes
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Applications
13.7.1. Acute Coronary Syndrome
13.7.2. Myocardial Infarction
13.7.3. Congestive Heart Failure
13.7.4. Cardiomyopathy
13.7.5. Ischemia
13.7.6. Myocarditis
13.7.7. Atrial Fibrillation
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by End Users
13.10.1. Laboratory Testing
13.10.2. Point of Care Testing
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Cardiac Biomarkers Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Cardiac Biomarkers Market: Market Share Analysis
14.2. Cardiac Biomarkers Distributors and Customers
14.3. Cardiac Biomarkers Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. Alere, Inc.,
14.4.2. Siemens Healthcare GmbH
14.4.3. Roche Diagnostics
14.4.4. Beckman Coulter, Inc.
14.4.5. Thermo Fisher Scientific, Inc.
14.4.6. Becton, Dickinson and Company
14.4.7. bioMérieux SA
14.4.8. Bio-R
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cardiac Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cardiac Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cardiac Biomarkers Market - Supply Chain
4.5. Global Cardiac Biomarkers Market Forecast
4.5.1. Cardiac Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cardiac Biomarkers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Cardiac Biomarkers Market Absolute $ Opportunity
5. Global Cardiac Biomarkers Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Cardiac Biomarkers Market Size and Volume Forecast by Types
5.3.1. Troponin
5.3.2. Creatine Kinase - MB (CK-MB)
5.3.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
5.3.4. Myoglobin
5.3.5. Ischemia Modified Albumin (IMA)
5.3.6. Heart-Type Fatty Acid Binding Protein
5.3.7. LDH Isoenzymes
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Cardiac Biomarkers Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Cardiac Biomarkers Market Size and Volume Forecast by Applications
6.3.1. Acute Coronary Syndrome
6.3.2. Myocardial Infarction
6.3.3. Congestive Heart Failure
6.3.4. Cardiomyopathy
6.3.5. Ischemia
6.3.6. Myocarditis
6.3.7. Atrial Fibrillation
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Cardiac Biomarkers Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Cardiac Biomarkers Market Size and Volume Forecast by End Users
7.3.1. Laboratory Testing
7.3.2. Point of Care Testing
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Cardiac Biomarkers Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cardiac Biomarkers Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cardiac Biomarkers Demand Share Forecast, 2019-2026
9. North America Cardiac Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cardiac Biomarkers Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cardiac Biomarkers Market Size and Volume Forecast by Types
9.4.1. Troponin
9.4.2. Creatine Kinase - MB (CK-MB)
9.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
9.4.4. Myoglobin
9.4.5. Ischemia Modified Albumin (IMA)
9.4.6. Heart-Type Fatty Acid Binding Protein
9.4.7. LDH Isoenzymes
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Cardiac Biomarkers Market Size and Volume Forecast by Applications
9.7.1. Acute Coronary Syndrome
9.7.2. Myocardial Infarction
9.7.3. Congestive Heart Failure
9.7.4. Cardiomyopathy
9.7.5. Ischemia
9.7.6. Myocarditis
9.7.7. Atrial Fibrillation
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Cardiac Biomarkers Market Size and Volume Forecast by End Users
9.10.1. Laboratory Testing
9.10.2. Point of Care Testing
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Cardiac Biomarkers Demand Share Forecast, 2019-2026
10. Latin America Cardiac Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Types
10.4.1. Troponin
10.4.2. Creatine Kinase - MB (CK-MB)
10.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
10.4.4. Myoglobin
10.4.5. Ischemia Modified Albumin (IMA)
10.4.6. Heart-Type Fatty Acid Binding Protein
10.4.7. LDH Isoenzymes
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Applications
10.7.1. Acute Coronary Syndrome
10.7.2. Myocardial Infarction
10.7.3. Congestive Heart Failure
10.7.4. Cardiomyopathy
10.7.5. Ischemia
10.7.6. Myocarditis
10.7.7. Atrial Fibrillation
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Cardiac Biomarkers Market Size and Volume Forecast by End Users
10.10.1. Laboratory Testing
10.10.2. Point of Care Testing
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Cardiac Biomarkers Demand Share Forecast, 2019-2026
11. Europe Cardiac Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cardiac Biomarkers Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cardiac Biomarkers Market Size and Volume Forecast by Types
11.4.1. Troponin
11.4.2. Creatine Kinase - MB (CK-MB)
11.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
11.4.4. Myoglobin
11.4.5. Ischemia Modified Albumin (IMA)
11.4.6. Heart-Type Fatty Acid Binding Protein
11.4.7. LDH Isoenzymes
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Cardiac Biomarkers Market Size and Volume Forecast by Applications
11.7.1. Acute Coronary Syndrome
11.7.2. Myocardial Infarction
11.7.3. Congestive Heart Failure
11.7.4. Cardiomyopathy
11.7.5. Ischemia
11.7.6. Myocarditis
11.7.7. Atrial Fibrillation
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Cardiac Biomarkers Market Size and Volume Forecast by End Users
11.10.1. Laboratory Testing
11.10.2. Point of Care Testing
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Cardiac Biomarkers Demand Share Forecast, 2019-2026
12. Asia Pacific Cardiac Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Types
12.4.1. Troponin
12.4.2. Creatine Kinase - MB (CK-MB)
12.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
12.4.4. Myoglobin
12.4.5. Ischemia Modified Albumin (IMA)
12.4.6. Heart-Type Fatty Acid Binding Protein
12.4.7. LDH Isoenzymes
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Applications
12.7.1. Acute Coronary Syndrome
12.7.2. Myocardial Infarction
12.7.3. Congestive Heart Failure
12.7.4. Cardiomyopathy
12.7.5. Ischemia
12.7.6. Myocarditis
12.7.7. Atrial Fibrillation
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by End Users
12.10.1. Laboratory Testing
12.10.2. Point of Care Testing
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Cardiac Biomarkers Demand Share Forecast, 2019-2026
13. Middle East & Africa Cardiac Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Types
13.4.1. Troponin
13.4.2. Creatine Kinase - MB (CK-MB)
13.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
13.4.4. Myoglobin
13.4.5. Ischemia Modified Albumin (IMA)
13.4.6. Heart-Type Fatty Acid Binding Protein
13.4.7. LDH Isoenzymes
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Applications
13.7.1. Acute Coronary Syndrome
13.7.2. Myocardial Infarction
13.7.3. Congestive Heart Failure
13.7.4. Cardiomyopathy
13.7.5. Ischemia
13.7.6. Myocarditis
13.7.7. Atrial Fibrillation
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by End Users
13.10.1. Laboratory Testing
13.10.2. Point of Care Testing
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Cardiac Biomarkers Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Cardiac Biomarkers Market: Market Share Analysis
14.2. Cardiac Biomarkers Distributors and Customers
14.3. Cardiac Biomarkers Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. Alere, Inc.,
14.4.2. Siemens Healthcare GmbH
14.4.3. Roche Diagnostics
14.4.4. Beckman Coulter, Inc.
14.4.5. Thermo Fisher Scientific, Inc.
14.4.6. Becton, Dickinson and Company
14.4.7. bioMérieux SA
14.4.8. Bio-R
Segments Covered in the Report
The global cardiac biomarkers market has been segmented on the basis of
Types
The global cardiac biomarkers market has been segmented on the basis of
Types
- Troponin
- Creatine Kinase - MB (CK-MB)
- Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
- Myoglobin
- Ischemia Modified Albumin (IMA)
- Heart-Type Fatty Acid Binding Protein
- LDH Isoenzymes
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Cardiomyopathy
- Ischemia
- Myocarditis
- Atrial Fibrillation
- Laboratory Testing
- Point of Care Testing
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Alere, Inc.,
- Siemens Healthcare GmbH
- Roche Diagnostics
- Beckman Coulter, Inc.
- Thermo Fisher Scientific, Inc.
- Becton, Dickinson and Company
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Randox Laboratories Ltd.
Key players competing in the cardiac biomarkers market are Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., and Randox Laboratories Ltd.
These companies are constantly focusing on generating growth by creating innovative product designs and new tests as well as improving the specificity of the tests. Alere, Inc., for example, made the Alere triage line, which combines three important biomarkers: CK-MB, myoglobin, and troponin I. This test is easy to use and popular since it is a hybrid tool and an effective point-of-care cardiac testing package.
Our Clients
Related Reports
Some other reports from this category!
